J&J and AbbVie also considered AtaiBeckley before Lilly’s $2.8 B acquisition
read at Endpoints ↗DealNeutral
Johnson & Johnson and AbbVie were reported to have evaluated AtaiBeckley as a potential target in the psychedelic market.
The companies did not submit an offer before Eli Lilly closed its $2.8 billion purchase of the firm.
Both J&J and AbbVie already hold psychedelic assets, underscoring their continued interest in expanding that therapeutic area.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “J&J, AbbVie said to have also looked at AtaiBeckley before Lilly’s $2.8B deal”
read at Endpoints ↗84 words · retrieved Jul 20
comments(0)
5-min edit window · permanent after that